Pharmacogenomics of endocrine therapy in breast cancer

Medicine & Life Sciences

• Pharmacogenetics 83%
• Tamoxifen 78%
• Breast Neoplasms 46%
• Cytochrome P-450 CYP2D6 46%
• afimoxifene 27%
• Pharmacogenomic Testing 24%
• Aromatase Inhibitors 22%
• Aromatase 22%
• 4-hydroxy-N-desmethyltamoxifen 15%
• Selective Estrogen Receptor Modulators 12%
• Therapeutics 12%
• Metabolic Activation 11%
• Hydroxylation 10%
• United States Food and Drug Administration 9%
• Genetic Variation 8%
• Drug-Related Side Effects and Adverse Reactions 8%
• Research Design 7%
• Parents 6%
• Genotype 6%
• Phenotype 5%
• Drug Therapy 5%
• Pharmaceutical Preparations 3%
• Genes 3%
• Neoplasms 2%

Chemical Compounds

• Tamoxifen 100%
• Cytochrome P450 39%
• Aromatase Inhibitor 27%
• Selective Estrogen Receptor Modulator 14%
• Metabolic Activation 11%
• Drug 9%
• DNA Sequence 9%
• Application 2%